Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles

Massimo Bonora; Mariusz R. Wieckowski; David A. Sinclair; Guido Kroemer; Paolo Pinton; Lorenzo Galluzzi

doi:10.1038/s41569-018-0074-0

Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles

Massimo Bonora, Mariusz R. Wieckowski, David A. Sinclair, Guido Kroemer, Paolo Pinton, Lorenzo Galluzzi

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

201 Citations (Scopus)

Résumé

A large body of evidence indicates that mitochondrial dysfunction has a major role in the pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary efforts have been focused on the development of agents that specifically target mitochondria for the treatment of cardiovascular disease. Despite such an intensive wave of investigation, no drugs specifically conceived to modulate mitochondrial functions are currently available for the clinical management of cardiovascular disease. In this Review, we discuss the therapeutic potential of targeting mitochondria in patients with cardiovascular disease, examine the obstacles that have restrained the development of mitochondria-targeting agents thus far, and identify strategies that might empower the full clinical potential of this approach.

langue originale	Anglais
Pages (de - à)	33-55
Nombre de pages	23
journal	Nature Reviews Cardiology
Volume	16
Numéro de publication	1
Les DOIs	https://doi.org/10.1038/s41569-018-0074-0
état	Publié - 1 janv. 2019

Accès au document

10.1038/s41569-018-0074-0

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{c8346e39f5824dae8df319df57967f17,

title = "Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles",

abstract = "A large body of evidence indicates that mitochondrial dysfunction has a major role in the pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary efforts have been focused on the development of agents that specifically target mitochondria for the treatment of cardiovascular disease. Despite such an intensive wave of investigation, no drugs specifically conceived to modulate mitochondrial functions are currently available for the clinical management of cardiovascular disease. In this Review, we discuss the therapeutic potential of targeting mitochondria in patients with cardiovascular disease, examine the obstacles that have restrained the development of mitochondria-targeting agents thus far, and identify strategies that might empower the full clinical potential of this approach.",

author = "Massimo Bonora and Wieckowski, {Mariusz R.} and Sinclair, {David A.} and Guido Kroemer and Paolo Pinton and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Nature Limited.",

year = "2019",

month = jan,

day = "1",

doi = "10.1038/s41569-018-0074-0",

language = "English",

volume = "16",

pages = "33--55",

journal = "Nature Reviews Cardiology",

issn = "1759-5002",

number = "1",

}

TY - JOUR

T1 - Targeting mitochondria for cardiovascular disorders

T2 - therapeutic potential and obstacles

AU - Bonora, Massimo

AU - Wieckowski, Mariusz R.

AU - Sinclair, David A.

AU - Kroemer, Guido

AU - Pinton, Paolo

AU - Galluzzi, Lorenzo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A large body of evidence indicates that mitochondrial dysfunction has a major role in the pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary efforts have been focused on the development of agents that specifically target mitochondria for the treatment of cardiovascular disease. Despite such an intensive wave of investigation, no drugs specifically conceived to modulate mitochondrial functions are currently available for the clinical management of cardiovascular disease. In this Review, we discuss the therapeutic potential of targeting mitochondria in patients with cardiovascular disease, examine the obstacles that have restrained the development of mitochondria-targeting agents thus far, and identify strategies that might empower the full clinical potential of this approach.

AB - A large body of evidence indicates that mitochondrial dysfunction has a major role in the pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary efforts have been focused on the development of agents that specifically target mitochondria for the treatment of cardiovascular disease. Despite such an intensive wave of investigation, no drugs specifically conceived to modulate mitochondrial functions are currently available for the clinical management of cardiovascular disease. In this Review, we discuss the therapeutic potential of targeting mitochondria in patients with cardiovascular disease, examine the obstacles that have restrained the development of mitochondria-targeting agents thus far, and identify strategies that might empower the full clinical potential of this approach.

UR - http://www.scopus.com/inward/record.url?scp=85053041945&partnerID=8YFLogxK

U2 - 10.1038/s41569-018-0074-0

DO - 10.1038/s41569-018-0074-0

M3 - Review article

C2 - 30177752

AN - SCOPUS:85053041945

SN - 1759-5002

VL - 16

SP - 33

EP - 55

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

IS - 1

ER -